Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilumimab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK): a randomized phase II study Grant uri icon

  •  
  • Overview
  •  
  • Affiliation
  •  
  • View All
  •  

abstract

  • Successful funding for the biomarker and correlative component of the phase II randomized study CYTOSHRINK

date/time interval

  • April 1, 2019 -

total award amount

  • CAD 489872